Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stock
Sunrest Lifescience Ltd (SUNREST) is currently trading at 39.45 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Sunrest Lifescience Limited specializes in marketing OTC generic pharmaceutical products across multiple states in India, such as Maharashtra and Gujarat. The company recently transitioned from a private to a public entity, marking its ambition for growth and greater market penetration. Their product portfolio is diverse, covering therapeutic areas like anti-bacterial, anti-diabetic, and nutraceuticals, signaling a broad customer reach. Sunrest Lifescience relies on Trilend Pharmaceuticals for product manufacturing, emphasizing an integrated group approach to operations.
Over the past 52 weeks, Sunrest Lifescience Ltd has traded between a low of ₹24.58 and a high of ₹45.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Sunrest Lifescience Ltd has a market capitalization of approximately 33.47. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Sunrest Lifescience Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 9.00 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 33.47 Cr, Sunrest Lifescience Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Sunrest Lifescience Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Sunrest Lifescience Ltd is 9.00. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Bearish
2
Neutral
8
Bullish
4
Bearish
3
Neutral
16
Bullish
27
Bearish
1
Neutral
8
Bullish
23
Bearish
2
Neutral
8
Bullish
4
Bearish
2
Neutral
8
Bullish
4
Bearish
1
Neutral
8
Bullish
23
Bearish
1
Neutral
8
Bullish
23
Bearish
1
Neutral
8
Bullish
23
Sunrest Lifescience Limited specializes in marketing OTC generic pharmaceutical products across multiple states in India, such as Maharashtra and Gujarat.
The company recently transitioned from a private to a public entity, marking its ambition for growth and greater market penetration.
Their product portfolio is diverse, covering therapeutic areas like anti-bacterial, anti-diabetic, and nutraceuticals, signaling a broad customer reach.
Sunrest Lifescience relies on Trilend Pharmaceuticals for product manufacturing, emphasizing an integrated group approach to operations.
Pharmaceuticals & Biotechnology
Pharmaceuticals
33 Cr
Low Risk
9.0
37.7
0.2
0.9
45.00
24.58
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
14.05 | 35 Cr | -1.51 | 4.11 | 0.00 | -117.84 | -25.84 | -37.84 | ||
31.20 | 34 Cr | -18.92 | 0.30 | 0.00 | -2.72 | -2.70 | -1.54 | ||
6.55 | 34 Cr | -2.03 | 0.68 | 0.00 | -26.30 | -22.21 | -24.96 | ||
39.45 | 33 Cr | 9.00 | 0.94 | 0.00 | 20.15 | 30.12 | 10.11 | ||
23.40 | 33 Cr | 5.56 | 0.88 | 0.00 | 15.82 | 19.17 | 11.89 | ||
10.15 | 32 Cr | 4.74 | 0.70 | 0.00 | 13.96 | 15.84 | 6.02 | ||
39.49 | 32 Cr | 15.36 | 3.28 | 0.00 | 25.62 | 29.29 | 8.47 | ||
| Median: 7 Co. | — | 23.40 | 33 Cr | 4.74 | 0.88 | 0.00 | 13.96 | 15.84 | 6.02 |
AGM/EGM Notice
Sunrest Lifescience Ltd submitted voting results and the scrutinizer's report for its 9th AGM held on 2026-09-07; resolutions (including re-appointments and material related party transactions) were approved and will be hosted on the company website.
AGM/EGM Notice
Sunrest Lifescience Limited informed exchanges of proceedings of its 9th AGM held on 2026-09-07 via VC/OAVM; adopted standalone & consolidated financials, re-appointed MD and Whole-time Director, and approved material RPTs for FY2026-27.
Regulatory/Compliance Filing
Sunrest Lifescience Ltd informed the Exchange that newspaper publications on Sept 03, 2026 notified extension of the Rights Issue closure date from September 02, 2026 to September 11, 2026.
